A recent Mendelian randomization and transcriptomic study identified TET2 as a shared gene signature, showing that genetically predicted AD was elated to a 17% lower likelihood of CRC (odds ratio (OR) 0.83, 95% CI 0.75–0.94) [23]. Here, TET2 is linked to colorectal carcinoma.